This medication may cause serious stomach or intestinal problems. Check with your doctor right away if you have belching, bloating or a feeling of fullness, blood in your stools, constipation, diarrhea, excess air or gas in your stomach, hiccups, nausea, stomach pain, annoying bloating around the anus, or vomiting. The FDA is aware of an adverse effect reported at a pharmacy that didn't actually make up the product, related to a product labeled as a compound tirzepatide. The adverse effect report included symptoms such as redness, swelling at the injection site, pain, and a red bump at the injection site.
Other common adverse effects include gastrointestinal problems such as nausea and vomiting, while serious adverse effects include semaglutid-induced pancreatitis, risk of diabetic retinopathy, acute gallbladder and kidney injury, etc. However, treatment with semaglutide is also associated with worrisome adverse effects such as acute pancreatitis, anaesthetic risks such as pulmonary aspiration or residual gastric contents, acute kidney injury, acute gallbladder injury, non-arteritic anterior ischaemic optic neuropathy and diabetic retinopathy. The potential anaesthetic risks of treatment with semaglutide justify careful consideration for ethical reasons. The SUSTAIN-6 trial provided compelling evidence of the cardiovascular benefits of semaglutide, and demonstrated a 26% reduction in the risk of serious adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
In a meta-analysis of 76 RCTs involving 103,371 patients, it was found that the use of GLP-1 AR was associated with an increased risk of gallbladder or biliary tract diseases, such as cholelithiasis, cholecystitis, and biliary disease. Its benefits go beyond glycemic control, and include weight reduction and anti-inflammatory effects, which together reduce cardiovascular risks. Semaglutide therapy may improve glycemic control, weight loss, and decrease cardiovascular risks, such as ischaemic stroke. This medication may be prescribed to lower the risk of a heart attack or stroke in people who have type 2 diabetes and a comorbid cardiovascular condition.
Oral and subcutaneous therapies with semaglutide have demonstrated their efficacy in improving glycemic control, weight loss and reducing cardiovascular risks associated with diabetes mellitus. Research has shown that exposure to the media, such as the tendency and glorification of taking Ozempic as a weight-loss medication, can increase the risk of eating disorders and symptoms. Semaglutide injection may increase your risk of developing thyroid tumors, including a type of thyroid cancer. These results contrast with those of previous studies, which indicate that semaglutide does not pose a significant risk of thyroid cancer.
Although there have been studies on the incidence of stroke in patients receiving semaglutide compared to specific treatment for type 2 diabetes, it is necessary to understand how treatments for type 2 diabetes generally compare to each other in reducing the risk of stroke. Although this is a unique case, it is necessary to understand if there is an association between the use of semaglutide for four years and the onset of potentially fatal pancreatic complications, aggravated risk factors and the mechanism by which they could occur. It can also be used to reduce the risk of stroke and heart attack in people with type 2 diabetes and a concurrent heart condition.
